中国在艾滋病疫苗研发领域取得重要进展，我国首个复制型天坛痘苗载体艾滋病疫苗I期临床试验

Core Insights - The Chinese Center for Disease Control and Prevention has completed the first Phase I clinical trial of a recombinant HIV vaccine using the Tian Tan strain of vaccinia virus as a vector, marking a significant advancement in HIV vaccine research in China [1] Group 1 - The study innovatively utilizes the "Tian Tan strain" of vaccinia virus, which was previously used to eradicate smallpox, as a carrier for the HIV vaccine [1] - The trial has verified the safety of the vaccine and its ability to elicit an effective immune response [1] - This development signifies an important milestone in the field of HIV vaccine research in China [1]